1. Healthcare

02 Feb 2015 13:49 HP Fax
page
Zydus
dedicated/4*g
to«/C'
1
Cadila
Healthcare Limited
Regd. Office :
'Zydus Tower':
Satellite Cross Roads,
Ahmedabad 380 015. India,
Phone . +91-79-26868100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L242306,11995PLC025878
February 2, 2015
Bombay Stock Exchange Limited
151 Floor, P.J Towers
Dalal Street
Kind Attn.: Mr. Sanjay Golecha
Mr. Gopalkrishnan
MUMBAI - 400001
National Stock Exchange of India Ud.
th
Exchange Plaza, 5 Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Kind Attn.; Famroze Pochara
Asst. Vice President
Bandra - (East)
Mumbai z 400 051
Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad z 380 015
Re.:
Press Release.
Dear Sir/Madam
We enclose herewith a copy of press release dated February 2, 2015 under the title "The
-th
Ramanbhai Foundation / International Research Symposium Advances in New Drug
Discovery and Development gets underway". The contents of the press release give full
details.
Please bring the aforesaid news to the notice of the members of the exchange and the
investors' at large.
Thankingyou,
Yours faithfully,
F
CADILA HEALTHCARE LIMITED
64«
UPEN H. SHAH
COMPANY SECRETARY
Encl.: As above.
02 Feb 2015 13:49 HP Fax
Zydus/
dedicated /1+
to L « C
page 2
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
-
The Ramanbhai Foundation 7 h International Research Symposium
Advances in New Drug Discovery and Development gets underway
Ahmedabad, 02 February 2015
The Ramanbhai Foundation 7a International Symposium on GAdvances in New Drug
Discovery and Development' got underway at YMCA today. Over the next two days,
internationally acclaimed scientists, researchers and academicians from India and across the
globe will be addressing the various aspects related to New Drug Discovery - with a focus on
diabetes, cardiometabolic diseases, NASH, inflammation and infectious diseases.
At the opening session today, the Nobel Laureate in Physiology or Medicine for the year
2012 and Distinguished Group Leader in the Wellcome Trust / CRUX Gurdon
Institute,
Cambridge, UK, Sir John Gurdon, delivered the keynote address. Sir Gurdon's pioneering
breakthrough resulted in the discovery that mature cells can be converted into Stom cells.
Speaking on the occasion, Mr. Pankaj R. Patel, Chief Patron of the Ramanbhai Foundation
7th International Symposium and Chairman and Managing Director, Zydus Cadila, said,
We
have been committed to the path of innovation and
discovery and this knowledge sharing
forum forms an important part of this endeavour. Our pharma innovation and bioinnovation
journey has been very heartening in our attempt to look at differentiated medicines for the
future. From APIs to vaccines, biosimilars and niche technologies, we have been exploring
different ideas and concepts that can bridge unmet healthcare needs."
New drug discovery and development tools and technologies derived
ftom biotechnology,
genomics, molecular modelling, and oomputational chemistry promise significant reductions
in oosts and development time required to bring new drugs to the market.
The symposium which will provide an insight into various aspects of drug discovery has an
eminent panel of speakers such as Dr. Jeff Kelly, Chairman, Department of Molecular and
Experimental Medicine, The Kelly Group, The Soripps Research Institute La Jolla, USA, Dr.
Gregory L. Verdine, Erving Professor of Chemistry, Harvard Department of Stem Cell and
Regenerative Biology, Harvard University, USA, Dr. Richard DiMarchi, Standiford H. Cox
Distinguished Professor of Chemistry, Linda & Jack Gill Chair in Biomotecular Soiences,
Indiana University, Dr. Rahul Singhvi, ScD COO, Global Vaccine Business Unit, Takeda
Pharmaceuticals, Inc. USA, Dr. Philip Larsen, Global Head of Diabetes Research and
Translational Science, Sanofi Aventis, Dr. Shaukat M. Sadikot President-Elect,
International Diabetes Federation 2013-2015, President of DiabetesIn(lia, Consultant
Endocrinology, Jaslok Hospital and Research Center, Dr. Matthias H. Tschop, Alexandervon-Humboldt Professor, Research Director, Helmholtz Diabetes Center, Director, Institute
for Diabetes and Obesity, Helmholtz Zentrum Munchen Chair, Division of Metabolic
Diseases, Department of Medicine, Technische Universitiit Munchen: Dr. Dhavalkumar D.
Patel, Head, Novartis Institute of Biomedical Research Europe, Basel, Switzerland, Dr.
Charles F. Burant, Dr. Robert C. and Veronica Atkins Professor of Metabolism, The Burant
1
For turlher information please contact:
The Corporate Communications Department
Cadlla Healthcare Umited
I 'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines) Fax: +91-79-26862365 www.zyduscadila.com
r.IN.1 92;lnA 11Qq5PI ('.095*7R
02 Feb 2015 13:49 HP Fax
page
3
Lab,University of Michigan Medical School, USA, Dr. Shashank R. Joshi, Consulting
Endocrinologist, Lilavati Hospital in Mumbai, India, Dr. Walter Wahli, Professor, Center
for Integrative Genomics, University of Lausanne, Switzerland, Professor of Metabolic
Disease, Lee Kong Chian School of Medicine, Imperial College London & Nanyang
Technological University, Singapore General Hospital, Singapore, Dr. Naga Chalasani, MI),
FACG; Professor of Medioine, Division of Gastroenterology and Hepatology, Indiana
University School of Medicine, USA to name a few.
Nearly 500 delegates from India and abroad are participating in the symposium which is
being held under the aegis ofthe Ramanbhai Foundation.
The Ramanbhai Foundation international symposium has been bringing together experts from
both the academia and industry across the world to share their insights on the latest
developments in pharmaceutical research.
The theme of the first international symposium in 2003 was Drug Discovery - the journey
from Mouse to Man. In 2005, the focus was on the Role of Genomics and Proteomies and in
2007 it was on the Advances in Diabetes Therapy. In 2009, the symposium looked at new
advances in Cardiometabolic disorders. In 2011, the topic was advances in Translational
Research and Medicine and in 2013 the theme was Advances in New Drug Discovery
Technologies And Translational Research.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops,
manufactures and markets a broad range of healthcare therapies. On the path of innovation,
the group employs over 16:500 people worldwide. Zydus' Innovation programme is
spearheaded by 1200 researchers across 19 sites. In 2013, the group was the first to identify
and develop Lipaglyn™ (Saroglitazar) and launch India's first NCE in the market. Recently,
the group launched Exemptia, the world's first biosimilar for Adalimumab, the largest selling
therapy worldwide for inflammatory arthritis.
***